Targeting heterogeneous depression with trazodone prolonged release: from neuropharmacology to clinical application
Trazodone PR is a versatile and well-tolerated treatment option for patients with comorbid conditions and treatment-resistant cases. Its multimodal action, combined with benefits like improved neuroplasticity through BDNF production, makes it a suitable choice for the long-term management of mood disorders and associated conditions [4-6].
Authors
- Leja Dolenc Grošelj
- Ante Silić (ORCID: https://orcid.org/0000-0003-2840-8836)
- Čedo Miljević (ORCID: https://orcid.org/0000-0002-8306-133X)
- Andrea M. Fagiolini (ORCID: https://orcid.org/0000-0001-5827-0853)
- Milan Latas (ORCID: https://orcid.org/0000-0001-8375-3865)
- Marina Šagud (ORCID: https://orcid.org/0000-0001-9620-2181)
- Alessandro Cuomo (ORCID: https://orcid.org/0000-0002-9211-5248)
Institutions
- University of Siena (IT)
- University of Ljubljana (SI)
- University of Zagreb (HR)
- Ljubljana University Medical Centre (SI)
- University of Belgrade (RS)
- European Faculty of Law (SI)
- Catholic University of Croatia (HR)
- Centar za Promociju Nauke (RS)
- Sisters of Charity Hospital (HR)
- Institute of Mental Health (RS)
Publication Details
- Journal
- Annals of General Psychiatry
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s12991-025-00563-z
- Citations
- 2
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 2.79